TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
RARE

Ultragenyx

Healthcare · Biotechnology

14.50$ +12.6% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement RARE
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
137,747.4% 0.0% 2.2% 8.7% 2.3% 4.6% 7.8% 10.4% 13.7% 16.2%
100.0% 100.0% 97.8% 91.3% 97.7% 95.4% 92.2% 89.6% 86.3% 83.8%
137,747.4% 8,868.5% 570.9% 344.6% 152.0% 141.5% 194.3% 149.3% 124.6% 111.4%
48,824.1% 3,825.0% 248.0% 155.7% 67.5% 62.6% 76.6% 71.3% 57.4% 51.9%
186,571.4% 12,693.5% 819.0% 500.3% 219.5% 204.1% 270.8% 220.7% 182.0% 163.3%
-186,471.4% -12,593.5% -721.2% -409.0% -121.8% -108.6% -178.6% -131.1% -95.7% -79.5%
0.0% 0.0% 0.0% 1.1% 12.3% 8.4% 11.8% 15.2% 11.3% 9.2%
-184,841.4% -12,187.5% -382.7% -385.1% -68.4% -128.9% -193.1% -140.1% -101.3% -84.8%
26.3% -620.2% 1.0% 3.2% 0.4% 0.3% 1.6% -0.4% 0.3% 0.6%
-184,867.7% -11,567.3% -383.7% -388.3% -68.8% -129.2% -194.7% -139.7% -101.6% -85.4%
-183,897.0% -12,370.5% -344.8% -375.8% -51.6% -116.8% -176.3% -118.9% -83.7% -70.4%

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?